

Exhibit No.	Description
1001	U.S. Patent No. 8,633,162 to Acheampong <i>et al.</i>
1002	Declaration of Dr. Mansoor Amiji
1003	<i>Curriculum Vitae</i> of Dr. Mansoor Amiji
1004	File history of U.S. Patent No. 8, 633,162 to Acheampong <i>et al.</i>
1005	File history of U.S. Patent Application No. 10/927,857, filed on August 27, 2010 to Acheampong <i>et al.</i>
1006	U.S. Patent No. 5,474,979 to Ding <i>et al.</i> , filed May 17, 1994
1007	K. Sall, <i>et al.</i> , <i>Two Multicenter, Randomized Studies of the Efficacy and Safety of Cyclosporine Ophthalmic Emulsion in Moderate to Severe Dry Eye Disease</i> , 107 OPTHALMOLOGY 631 (2000)
1008	A. Acheampong <i>et al.</i> , <i>Cyclosporine distribution into the conjunctiva, cornea, lacrimal gland, and systemic blood following topical dosing of cyclosporine to rabbit, dog, and human eyes</i> , 2 LACRIMAL GLAND, TEAR FILM, AND DRY EYE SYNDROMES 1001 (1998)
1009	U.S. Patent No. 5,578,586 to Glonek <i>et al.</i> , filed February 4, 1994
1010	U.S. Patent No. 5,981,607 to Ding <i>et al.</i> , filed January 20, 1998
1011	R. Kaswan, <i>Intraocular Penetration of Topically Applied Cyclosporine</i> 20 TRANSPL. PROC. 650 (1988)

1012	K. Kunert <i>et al.</i> , <i>Analysis of Topical Cyclosporine Treatment of Patients with Dry Eye Syndrome</i> 118 ARCH OPHTHALMOL 1489 (2000)
1013	Physicians' Desk Reference for Ophthalmic Medicines, 1999
1014	K. Turner <i>et al.</i> , <i>Interleukin-6 Levels in the Conjunctival Epithelium of Patients with Dry Eye Disease Treated with Cyclosporine Ophthalmic Emulsion</i> 19 CORNEA 492 (2000)
1015	D. Stevenson <i>et al.</i> <i>Efficacy and Safety of Cyclosporin A Ophthalmic Emulsion in the Treatment of Moderate-to-Severe Dry Eye Disease</i> 107 OPHTHALMOL. 967 (2000)
1016	REMINGTON'S 20 <sup>TH</sup> EDITION: THE SCIENCE AND PRACTICE OF PHARMACY (A. Gennaro ed. 2003)
1017	E. Goto <i>et al.</i> <i>Low-Concentration Homogenized Castor Oil Eye Drops for Noninflamed Obstructive Meibomian Gland Dysfunction</i> 109 OPHTHALMOL. 2030 (2002)
1018	A. Kanpolat <i>et al.</i> , <i>Penetration of Cyclosporin A into the Rabbit Cornea and Aqueous Humor after Topical Drop and Collagen Shield Administration</i> 20 CLAO J 119 (1994)
1019	A. Vieira <i>et al.</i> , <i>Effect of ricinoleic acid in acute and subchronic experimental models of inflammation</i> , 9 MED. INFLAMM. 223 (2000)
1020	R. Murphy, <i>The Once and Future Treatment of Dry Eye</i> , REVIEW OF OPTOMETRY 1 (2000)
1021	D. Small <i>et al.</i> , <i>Blood concentrations of Cyclosporin A During Long-Term Treatment with Cyclosporin A Ophthalmic</i>

	<i>Emulsions in Patients with Moderate to Severe Dry Eye Disease</i> 18 J. OC. PHARM. THERAP. 411 (2002)
1022	STEDMAN'S MEDICAL DICTIONARY 27 <sup>TH</sup> EDITION (M.B. Pugh ed. 2000)
1023	Complaint; <i>Allergan, Inc. v. Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries Ltd., Apotex, Inc., Apotex Corp., Akorn, Inc., Mylan Pharmaceuticals Inc., and Mylan Inc.</i> , No. 2:15-cv-01455
1024	Approved Drug Products with Therapeutic Equivalence Evaluations (34th Ed.) (2014) (Excerpts)
1025	Declaration of Dr. Walter Chambliss
1026	<i>Curriculum Vitae</i> of Dr. Walter Chambliss